不用本金就能赚钱的方法

来宝网Logo

热门词:生物显微镜 水质分析仪 微波消解 荧光定量PCR 电化学工作站 生物安全柜

现在位置不用本金就能赚钱的方法>技术资料不用本金就能赚钱的方法>行业动态>公司动态>默克雪兰诺和Philochem签订生育技术领域研究协议

默克雪兰诺和Philochem签订生育技术领域研究协议

默克雪兰诺2011年2月10日 14:05 点击:3405

德国默克雪兰诺Merck Serono   瑞士Philochem



2010 年12 月21 日,瑞士日内瓦–总部位于德国达姆施塔特市的默克集团旗下的
制药业务分支默克雪兰诺公司今天宣布,与瑞士Philochem AG 公司(意大利Philogen
S.p.A.的研究机构)达成战略协议。根据协议条款,Philochem 将向默克雪兰诺提供特
异性单克隆抗体,用以研究卵母细胞及胚胎质量的分子生物标记物。协议的详细内容没
有透露。协议一旦生效,分子生物标记物将被用于发展预测性或诊断性测试,从而帮助医生
客观评估卵母细胞和胚胎质量。
“我们确信用以评估卵母细胞和胚胎质量的新型无创诊断测试技术的发展可以帮
助试管婴儿胚胎植入领域的专家为不孕夫妻提供实现拥有自己孩子的梦想的最佳机
会。”默克雪兰诺执行副总裁及全球研发负责人Bernhard Kirschbaum 说。
“Philochem 在分子特异性结合的筛选方面经验丰富。我们很高兴能够和默克雪兰
诺签订此项生育研究领域的合作协议,我们期望能够对试管婴儿胚胎植入技术的进步做
出贡献。”Philochem AG 公司研究部总监Eveline Trachsel 博士说。
默克雪兰诺在生育治疗领域处于世界领先水平。公司致力于发展并提供富于创新且
易于使用的产品和设备,以及用以帮助处于生殖周期不同阶段(从卵泡发育阶段到早期
妊娠阶段)的不孕夫妻的新技术。
关于默克雪兰诺及生育治疗
默克雪兰诺在生殖治疗领域处于世界领先水平,是唯一一家可提供针对生殖周期各个阶段的全套生育
药物,以及治疗不孕症所需的重组三种激素的公司:果纳芬®(促卵泡激素),刺激女性卵巢产生卵子并且
催生男性精子;乐芮®(促黄体激素),刺激黄体生成素极度缺乏女性的卵泡发育;艾泽®(绒促性素),帮
助卵子成熟并释放卵子;Pergoveris®(促卵泡激素/促黄体激素)刺激黄体生成素及卵泡刺激素严重缺乏女
性的卵泡发育;思则凯®(醋酸西曲瑞克)防止提早排卵;雪诺同®(黄体酮凝胶),帮助建立并维持妊娠。
不是所有的产品都已上市。
2/2
关于默克雪兰诺公司
默克雪兰诺是总部位于德国达姆施塔特的全球医药和化工集团默克公司旗下创新的处方药业务分支。
默克雪兰诺总部设在瑞士日内瓦,致力于发现、开发、生产和销售创新的小分子和生物制药产品,帮助患
者解决其尚未满足的医疗需求。其北美业务在美国和加拿大以EMD 雪兰诺的名称运营。默克雪兰诺服务
于患者的领导品牌有:治疗癌症的爱必妥®,治疗多发性硬化症的利比®、治疗不孕症的果纳芬®、治疗内
分泌和代谢紊乱的思真®、Serostim®和Kuvan®、治疗心血管和代谢疾病的Glucophage®、康忻®和优甲
乐®。不是所有的产品在每个国家都有销售。公司每年研发投入超过10 亿欧元,专注于发展专科治疗领域
业务,包括神经变性疾病、肿瘤、生殖与内分泌,还包括在自身免疫与炎症性疾病的研究与开发中崭露头
角的新领域等。
默克雪兰诺公司成立后,原德国默克公司在中国的处方药分公司和瑞士雪兰诺公司中国分部有机整合
成为默克雪兰诺中国处方药公司。默克雪兰诺中国总部位于北京,现有员工1200 余名,业务遍及全国。
默克雪兰诺中国的主要产品领域包括:基础医疗领域-包括心血管产品、甲状腺产品、外科及急症产品、生
长激素产品和抗过敏产品;妇女保健和生殖领域;神经病变领域和抗肿瘤领域。主要品牌有:抗肿瘤领域
产品爱必妥®、治疗多发性硬化的利比®、抗高血压药康忻®、心绞痛药物喜格迈®,抗过敏产品阿罗格®、
甲状腺产品优甲乐®、赛治®、外科及急症产品思他宁®和生长激素产品思真®、治疗多发性硬化的利比®、
生殖领域的果纳芬®、思则凯®、乐芮®、艾泽®、雪诺同®、妇女保健产品可宝净®、更宝芬®、松奇®等。
欲了解更多信息,请访问: 或
关于默克集团
默克是全球化的医药与化工集团,2009 年营业额达77 亿欧元。公司创建于1668 年,目前在全球
64 个国家拥有约40,000 名员工(包括默克密理博)。默克的成功来自其富有开创性精神的员工的不断创新。
德国默克集团(Merck KGaA)主导默克在全球的经营活动。默克家族迄今保有70%的股权,其余30%由
自由股东持有。1917 年,美国子公司默沙东公司的所有权被剥夺,自此以后便成为一家独立公司。
欲了解更多信息,请访问: 。
新闻联系人:
默克雪兰诺企业传播部 熊吉莹/孙正洁
电话: (010) 5907 2688 -2539/2538
邮件: jenny.xiong@merckserono.cn
sophie.sun@merckserono.cn


Geneva, Switzerland, December 21, 2010 – Merck Serono, the pharmaceutical division
of Merck KGaA, Darmstadt, Germany, today announced a strategic agreement with
Philochem AG, Switzerland, the research unit of Philogen S.p.A., Italy. Under the terms
of the agreement, Philochem will supply specific monoclonal antibodies to Merck
Serono, to be used in the search for molecular biomarkers of oocyte and embryo
quality. Further terms of the agreement are not disclosed.
Once validated, molecular biomarkers can be used for the development of predictive or
diagnostic tests that can help physicians assess objectively oocyte and embryo quality.
"We are convinced that the development of innovative non-invasive diagnostic tests to
evaluate oocyte and embryo quality could help In Vitro Fertilization specialists offer
infertile couples the best chance of achieving their dream of having a baby on their
own," said Bernhard Kirschbaum, Executive Vice President, Head of Global Research
and Development at Merck Serono.
“Philochem has a considerable track record in the isolation of specific binding
molecules. We are delighted to enter into this collaborative agreement with Merck
Serono in the area of fertility and we look forward to contributing to the advancement of
In Vitro Fertilization techniques,” said Dr. Eveline Trachsel, Director of Research, at
Philochem AG.
Merck Serono is the world leader in fertility treatments. The company’s vision is to
develop and provide innovative, easy-to-use products and devices, as well as new
News Release
Page 2 of 2
technologies to help infertile couples at every stage of the reproductive cycle: from
follicular development to early pregnancy.
About Merck Serono and Fertility Treatment
Merck Serono is the world leader in fertility treatments, and the only company to offer a full portfolio of
fertility drugs for every stage of the reproductive cycle and recombinant versions of the three hormones
needed to treat infertility: GONAL-f® (follitropin alfa), to stimulate the ovaries and produce eggs in women
and spermatogenesis induction in men; Luveris® (lutropin alfa), to stimulate follicular development in
women who are profoundly LH deficient; Ovitrelle® (choriogonadotropin alfa), to help follicles mature and
release eggs; Pergoveris® (follitropin alfa/lutropin alfa) to stimulate follicular development in women with
severe LH and FSH deficiency; Cetrotide® (cetrorelix acetate) to prevent a premature ovulation; and
Crinone® (progesterone gel), to help establish and maintain a pregnancy. Not all products are available in
all markets.
About Merck Serono
Merck Serono is the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, a global
pharmaceutical and chemical company. Headquartered in Geneva, Switzerland, Merck Serono discovers,
develops, manufactures and markets prescription medicines of both chemical and biological origin in
specialist indications. In the United States and Canada, EMD Serono operates through separately
incorporated affiliates.
Merck Serono has leading brands serving patients with cancer (Erbitux®, cetuximab), multiple sclerosis
(Rebif®, interferon beta-1a), infertility (Gonal-f®, follitropin alfa), endocrine and metabolic disorders
(Saizen® and Serostim®, somatropin), (Kuvan®, sapropterin dihydrochloride) as well as cardiometabolic
diseases (Glucophage®, metformin), (Concor®, bisoprolol), (Euthyrox®, levothyroxine). Not all products
are available in all markets.
With an annual R&D expenditure of over € 1bn, Merck Serono is committed to growing its business in
specialist-focused therapeutic areas including neurodegenerative diseases, oncology, fertility and
endocrinology, as well as new areas potentially arising out of research and development in rheumatology.
About Merck
Merck is a global pharmaceutical and chemical company with total revenues of € 7.7 billion in 2009, a
history that began in 1668, and a future shaped by approximately 40,000 (including Merck Millipore)
employees in 64 countries. Its success is characterized by innovations from entrepreneurial employees.
Merck's operating activities come under the umbrella of Merck KGaA, in which the Merck family holds an
approximately 70% interest and free shareholders own the remaining approximately 30%. In 1917 the U.S.
subsidiary Merck & Co. was expropriated and has been an independent company ever since.
For more information, please visit or

(来源: 默克雪兰诺 )


全年征稿 / 资讯合作

联系邮箱:kefu@strauss-usa.com不用本金就能赚钱的方法

BANQUANYUMIANZESHENGMING

  • 凡本网注明“来源:来宝网”的所有作品,版权均属于来宝网,转载请必须注明来宝网, http://strauss-usa.com,违反者本网将追究相关法律责任。
  • 本网转载并注明自其它来源的作品,目的在于传递更多信息,并不代表本网赞同其观点或证实其内容的真实性,不承担此类作品侵权行为的直接责任及连带责任。其他媒体、网站或个人从本网转载时,必须保留本网注明的作品来源,并自负版权等法律责任。
  • 如涉及作品内容、版权等问题,请在作品发表之日起一周内与本网联系,否则视为放弃相关权利。


湖南快乐十分 湖南快乐十分 福建快3走势图0 福建快3走势图 河南快3走势图 河南快3走势图 广东11选5开奖结果 福建11选5走势图